This market research report includes a detailed segmentation of the global peptide therapeutics market by route of administration (parenteral, oral, pulmonary, and mucosal), by drug class (somatostatins, vasopressin, calcitonin, LHRH, glucagon and analogs, and insulins), and by synthesis technology (liquid-phase peptide synthesis, solid-phase peptide synthesis, and hybrid peptide synthesis). The top vendors analyzed in this report are Eli Lilly, Novo Nordisk, Sanofi, Takeda, and Teva.
Technavio’s market research analysts estimate the global peptide therapeutics market, to grow at a CAGR of around 8% between 2016 and 2020. Peptides are the most potent biologically active substances used to trigger, control, and maintain an individual’s physiological processes. The growing prevalence of cancer, metabolic, and cardiovascular diseases; presence of unmet needs; and the expected launch of pipeline peptide molecules to treat chronic diseases are driving the growth of peptide therapeutics market. The Americas lead this market, owing to the recent rise in the incidence of cancer, hepatitis, and metabolic disorders, advances in peptide synthesis technology, and the augmented consumption of various peptide therapies.
The new market research report from Technavio provides a breakdown and analysis of the peptide segments by technology.
“Of late, the market is witnessing a considerable shift towards untapped regions. Several vendors of peptide therapeutics are moving to developing economies due to the presence of large population groups and clinical trial subjects. Factors such as the presence of lenient regulatory guidelines, low manufacturing costs, skilled labor, and limited market competition will compel vendors to shift their manufacturing processes to the developing countries,” Imran Mushtaq, Industry Manager, Healthcare & Lifesciences, Technavio Research
The parenteral segment is the largest market segment in the global peptide therapeutics market. Currently, this segment dominates the market and is expected to retain its hold over the market until 2020 owing to factors like the higher bioavailability of drugs. Since the drugs administered through this route are absorbed quickly, it will result in the faster onset of action compared to other routes.
The key vendors in the global peptide therapeutics market are Eli Lilly, Novo Nordisk, Sanofi, Takeda, and Teva. The market is highly fragmented because of the presence of numerous small and large vendors. The vendors in the market compete on the basis of price, quality, and innovation. The high level of competition among the vendors has led to an increase in the number of M&As; wherein smaller entities are being acquired by or are being merged with, major players.
A more detailed analysis is available in the Technavio report, Global Peptide Therapeutics Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
